Mycirq (Ethinylestradiol, Etonogestrel)

Ethinylestradiol activates estrogen receptors while etonogestrel activates progesterone receptors. Together they suppress the hypothalamic‑pituitary‑ovarian axis, lowering gonadotropin release, preventing follicular development, and thickening cervical mucus, which collectively inhibit fertilisation.

The dosing regimen for Mycirq is determined by the prescribing healthcare professional. The product is supplied as a pre‑filled vaginal ring that is typically inserted and left in place for a specified period before replacement, as directed by the prescriber.

Mycirq is classified as pregnancy category X, meaning it must not be used by women who are pregnant or may become pregnant. It is also not recommended during breastfeeding because hormonal exposure could affect milk production and the infant.

To order Mycirq, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Mycirq offers continuous low‑dose hormone delivery via a vaginal ring, which can improve adherence compared with daily oral pills. Unlike injectables, it is removable and does not require healthcare‑provider administration, providing a discreet, reversible option within the combined estrogen‑progestogen class.

Mycirq should be stored at room temperature, below 25 °C, in its original packaging. Protect the ring from moisture, direct sunlight and extreme temperatures to maintain its integrity throughout its shelf life.

Mycirq is a flexible vaginal ring that is inserted into the vagina by the user according to the prescriber’s instructions. The ring remains in place for the recommended usage period, after which it is removed and a new ring is inserted.

The most serious risks include thromboembolic events such as deep vein thrombosis and pulmonary embolism, as well as rare severe allergic reactions (anaphylaxis). Women with a history of clotting disorders, smoking over age 35, or certain cardiovascular conditions should be evaluated carefully before use.

Mycirq is contraindicated in women who are pregnant, have known or suspected breast cancer, have a history of thromboembolic disease, are smokers over 35 years old, or have uncontrolled hypertension. It should also be avoided in individuals with severe liver disease or known hypersensitivity to its ingredients.